Pharmacokinetics of LB20304, a new fluoroquinolone, in rats and dogs

Archives of Pharmacal Research

Volumn 19, Issue 5, 1996, Pages 359-367

  Seo, Mi Kyeong ^a   Lee, Sun Hwa ^a   Choi, Yun Jeong ^a   Jeong, Yi Na ^a   Lee, Sung Hack ^a   Kim, In Chull ^a   Lee, Yong Hee ^a  

^a LG Chemical Ltd   (South Korea)

Author keywords

Dogs; Fluoroquinolone; LB20304; Pharmacokinetics; Rats

Indexed keywords

EID: 0000853149     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02976379     Document Type: Article

References (26)

1. Blumberg, H.M., Rimland, D., Caroll, D.J., Ty, P. and Wachsmuth, I.K., Rapid development of ciprofloxacin resistance in methicillin-susceptible and - resistant Staphylococcus aureus. J. Infect. Dis., 163, 1279-1285 (1991).
2. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-54 (1976).
3. Chiou, W.L., Critical evaluation of potential or in pharmacokinetic studies using the linear trapeizoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokin. Biopharm., 6, 539-546 (1978).
4. Czygan, P., Greim, H., Garro, A.J., Hutterer, F., Schaffner, F., Popper, H., Rosenthal, O. and Cooper, D.Y., Microsomal metabolism of dimethylnitrosamine and the cytochrome P-450 dependency of its activation to a mutagen. Cancer Res., 33, 2983-2986 (1973).
5. Dragnev, K.H., Beebe, L.E., Jones, C.R., Fox, S.D., Thomas, P.E., Nims, R.W. and Lubet, R.A., Subchronic dietary exposure to aroclor 1254 in rats: accumulation of PCBs in liver, blood, and adipose tissue and its relationship to induction of various hepatic drug-metabolizing enzymes. Toxicol. Appl. Pharmacol., 125, 111-122 (1994).
6. Fuchs, P.C., Barry, A.L., Pfaller, M.A., Allen, S.D. and Gerlach, E.H., Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD-131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob. Agents Chermother., 35, 764-766 (1991).
7. 14C]AT-2266 I. Single administration. Chemotherapy, 32, 117-135 (1984).
8. Gibaldi, M. and Pier, D., Pharmacokinetics. 2nd ed., Marcel Dekker, New York (1982).
9. Gilfillan, E.C., Pelak, B.A., Bland, J.A., Malatesta, P.F. and Gadebusch, H.H., Pharmacokinetic studies of norfloxacin in laboratory animals. Chemotherapy, 30, 288-296 (1984).
10. Jones, R.N., Fluoroquinolone resistance, an evolving national problem or just a problem for some physicians? Diag. Microbial. Infect. Dis., 15, 177-179 (1992).
11. Kaatz, G.W., Seo, S.M. and Ruble, C.A., Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J. Infect. Dis., 163, 1080-1086 (1991).
12. Kasajima, H., Ishikawa, N., Machida, M., Uchida, H. and Irikura, T., Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. Antimicrob. Agents Chermother., 30, 304-309 (1986).
13. Kim, M.Y., Oh, J.I., Paek, K.S., Hong, C.Y., Kim, I.C. and Kwak, J.H., In vitro activities of LB20304, a new fluoroquinolone. Arch. Pharm. Res., 19, 52-59 (1996).
14. Montay, G., Goueffon, Y. and Roquet, F., Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob. Agents Chermother., 25, 463-472 (1984).
15. Nakamura, S., Kurobe, N., Ohue, T., Hashimoto, M. and Shimizu, M., Pharmacokinetics of a novel quinolone AT-4140 in animals. Antimicrob. Agents Chemother., 34, 89-441 (1990).
16. Oh, J.I., Paek, K.S., Ahn, M.J., Kim, M.Y., Hong, C.Y., Kim, I.C. and Kwak, J.H., In vitro and in vivo evaluations of LB20304, a new fluoroquinolone. Antimicrob. Agents Chemother., 40, 1564-1568 (1996).
17. Okazaki, O., Kuruta, T., Hashimoto, K., Sudo, K., Tsumura, M. and Tachizawa, H., Metabolic disposition of DL-8280 the second report: absorption, distribution, and excretion of [14C]-DL-8280 in various animal species. Chemotherapy, 32, 1185-1202 (1984).
18. Okezaki, E., Terasaki, T. and Nakamura, M. Serum protein binding of lomefloxacin, a new antimicrobial agent, and its related quinolones. J. Pharm. Sci., 78, 504-507 (1989).
19. Ooie, T., Suzuki, H., Terasaki, T. and Sugiyama, Y., Characterization of the transport properties of a quinolone antibiotic, fleroxacin, in rat choroid plexus. Pharm. Res., 13, 523-527 (1996).
20. Piddock, L.J.B., New quinolones and gram-positive bacteria. Antimicrob. Agents Chermother., 38, 163-169 (1994).
21. Raviglione, M.C., Boyle, J.F., Mariuz, P., PablosMendez, A., Cotes, H. and Merlo, A., Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob. Agents Chemother., 34, 2050-2054 (1990).
22. Sato, K., Hosino, K., Tanaka, M., Hayakawa, I. and Osada, Y., Antimicrobial activity of DU-6859a, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chermother., 36, 1491-1498 (1992).
23. Siefert, H.M., Maruhn, D. and Scholl, H., Pharmacokinetics of ciprofloxacin 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C]ciprofloxacin in albino rats. Arzneim. Forsch./ Drug Res., 36, 1503-1510 (1986a).
24. Siefert, H.M., Maruhn, D., Maul, W., Forster, D. and Ritter, W., Pharmacokinetics of ciprofloxacin 1nd communication: absorption, concentrations in plasma, metabolism, and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. Arzneim. Forsch./Drug Res., 36, 1496-1502 (1986b).
25. Sugino, A., Peebles, C.L., Kruezer, K.N. and Cozzarelli, N.R., Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc. Natl. Acad. Sci. USA, 74, 4767-4771 (1977).
26. Thys, J.P., Jacobs, F. and Motte, S., Quinolones in the treatment of lower respiratory tract infections. Rev. Infect. Dis., 11 (Suppl. 5), S1212-S1219 (1989).